$TVRD

Chardan initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a buy rating and $8.00 price target, contingent on raising $35-40M for ulcerative colitis trials. The stock trades at $0.97, down 84% YoY, with a $15M market cap. Chardan estimates $1.6B peak sales at 20% success probability. H.C. Wainwright and Lucid Capital also rated TVRD Buy with $9.00 and $14.00 targets, respectively, citing positive clinical data.

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.

Tvardi Therapeutics (TVRD) shares rose about 42% after the company reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor, citing improved tolerability and target engagement. The stock was about $2.885 on Nasdaq, up 42.04%, after opening at $2.16 and reaching $3.01.

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001346830 0001346830 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

The heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.